CUI stringlengths 8 8 | STR stringlengths 1 2.86k ⌀ | SAB stringclasses 101
values |
|---|---|---|
C0013166 | Drug Containers and Closures | MSH |
C0013167 | Drug Contamination | MSH |
C0013168 | Drug Control | MSH |
C0013170 | Drug habituation | MTH |
C0013171 | Drug Design | MSH |
C0013173 | Drug eruption, salicylates | SNM |
C0013175 | Drug Evaluation | MTH |
C0013178 | Evaluation Studies, FDA Phase III as Topic | MSH |
C0013179 | Drug Evaluation, FDA Phase IV as Topic | MTH |
C0013182 | Drug Allergy | MTH |
C0013183 | Drug Implants | MTH |
C0013184 | Drug Incompatibility | MSH |
C0013185 | Drug Industry | MTH |
C0013186 | Drug Information Services | MSH |
C0013187 | Drug Infusion Systems | MSH |
C0013191 | Drug Labeling | MTH |
C0013193 | Drug Modeling | MSH |
C0013194 | Drug Packaging | MTH |
C0013196 | Drug pigmentation | SNOMEDCT_US |
C0013200 | Drug Recalls | MSH |
C0013201 | Drug Regulations | MSH |
C0013202 | Drug Residues | MSH |
C0013203 | Drug resistance | MTH |
C0013205 | Drug Resistance, Microbial | MTH |
C0013206 | Drug Evaluation, Preclinical | MTH |
C0013207 | Drug Screening Assays, Antitumor | MSH |
C0013210 | Drug Stability | MSH |
C0013211 | Drug Storage | MSH |
C0013213 | Drug Surveillance, Postmarketing | MSH |
C0013215 | Drug Synergism | MSH |
C0013216 | Pharmacotherapy | MTH |
C0013217 | pharmacotherapeutic | MTH |
C0013218 | Combination Drug Therapy | MTH |
C0013219 | Drug Therapy, Computer-Assisted | MSH |
C0013220 | Drug Tolerance | MTH |
C0013221 | Drug toxicity | MTH |
C0013222 | Drug Use Disorders | MTH |
C0013223 | Drug Utilization | MSH |
C0013226 | Drug-induced peptic ulcer | SNOMEDCT_US |
C0013227 | Pharmaceutical Preparations | MTH |
C0013229 | Drugs, Chinese Herbal | MSH |
C0013230 | Investigational New Drugs | MTH |
C0013231 | Drugs, Non-Prescription | MTH |
C0013232 | Drugs, Orphan | MSH |
C0013238 | Dry Eye Syndromes | MTH |
C0013239 | Dry Ice | MSH |
C0013240 | Alveolar periostitis | MTH |
C0013254 | pentetic acid | MTH |
C0013256 | DU-21220 | MSH |
C0013257 | Dual Data Collection | MSH |
C0013259 | Dual Personality | MSH |
C0013260 | Dual-Photon Absorptiometry | MSH |
C0013261 | Duane Retraction Syndrome | MTH |
C0013264 | Muscular Dystrophy, Duchenne | MTH |
C0013268 | Ducks | MTH |
C0013273 | Structure of ductus arteriosus | MTH |
C0013274 | Patent ductus arteriosus | MTH |
C0013277 | Due Process | MSH |
C0013278 | Duffy Blood group system | MTH |
C0013279 | Dugesia <flatworms> | MTH |
C0013283 | Galactitol | MSH |
C0013288 | Dumping Syndrome | MTH |
C0013289 | Duodenal Diseases | MSH |
C0013291 | Duodenal Neoplasms | MTH |
C0013292 | Duodenal Obstruction | MTH |
C0013293 | Greater duodenal papilla structure | MTH |
C0013294 | Lesser duodenal papilla structure | MTH |
C0013295 | Duodenal Ulcer | MTH |
C0013298 | Duodenitis | MTH |
C0013299 | Duodenogastric Reflux | MSH |
C0013300 | Duodenorrhaphy | SNOMEDCT_US |
C0013301 | Duodenoscopy | MSH |
C0013302 | Duodenostomy | MSH |
C0013303 | Duodenum | MTH |
C0013312 | Dupuytren Contracture | MTH |
C0013313 | Dura Mater | MTH |
C0013314 | Durable Medical Equipment | MTH |
C0013326 | Duromine | RXNORM |
C0013328 | Chlorpyrifos | MSH |
C0013330 | Dust | MTH |
C0013331 | Dutch Population | MTH |
C0013333 | Duvadilan | MSH |
C0013336 | Dwarfism | MTH |
C0013338 | Pituitary dwarfism | MTH |
C0013340 | dydrogesterone | MTH |
C0013341 | Dye Dilution Technique | MSH |
C0013342 | Dye Exclusion Assays, Antitumor | MSH |
C0013343 | Dyes | MTH |
C0013345 | Fonofos | MSH |
C0013349 | Dynamite | MSH |
C0013350 | Dynapen | RXNORM |
C0013352 | Dynein ATPase | MTH |
C0013354 | Dyneric | MSH |
C0013355 | Dynorphins | MTH |
C0013360 | dyphylline | MTH |
C0013362 | Dysarthria | MTH |
C0013363 | Dysautonomia | MTH |
C0013364 | Dysautonomia, Familial | MTH |
C0013366 | Dyschondroplasias | MTH |
C0013367 | PIGMENTATION DISORDERS, DRUG ERUPTIONS AND DISORDERS DUE TO PHYSICAL AGENTS | SNMI |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.